Free Trial
→ $5,000 DOGE check? (From Altimetry) (Ad)

Inhibrx Q3 2023 Earnings Report

Inhibrx logo
$12.56 -0.24 (-1.88%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Inhibrx EPS Results

Actual EPS
-$1.10
Consensus EPS
-$1.01
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Inhibrx Revenue Results

Actual Revenue
$0.12 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inhibrx Announcement Details

Quarter
Q3 2023
Date
11/9/2023
Time
N/A

Conference Call Resources

Inhibrx Earnings Headlines

Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead
January 22, 2025 | msn.com
Inhibrx Biosciences Inc (INBX) Gets a Hold from JMP Securities
January 22, 2025 | markets.businessinsider.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 22, 2025 | Altimetry (Ad)
Inhibrx reports promising ozekibart trial results
January 22, 2025 | msn.com
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
January 21, 2025 | prnewswire.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
January 13, 2025 | prnewswire.com
See More Inhibrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx and other key companies, straight to your email.

About Inhibrx

Inhibrx (NASDAQ:INBX), a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

View Inhibrx Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles